BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 27175930)

  • 1. Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer.
    Diessner J; Wischnewsky M; Stüber T; Stein R; Krockenberger M; Häusler S; Janni W; Kreienberg R; Blettner M; Schwentner L; Wöckel A; Bartmann C
    BMC Cancer; 2016 May; 16():307. PubMed ID: 27175930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.
    Thangarajah F; Vogel C; Pahmeyer C; Eichler C; Holtschmidt J; Ratiu D; Mallmann P; Malter W
    Anticancer Res; 2018 Oct; 38(10):6023-6026. PubMed ID: 30275235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.
    Falck AK; Bendahl PO; Chebil G; Olsson H; Fernö M; Rydén L
    Breast Cancer Res Treat; 2013 Jul; 140(1):93-104. PubMed ID: 23807420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
    Li X; Zhang X; Liu J; Shen Y
    BMC Cancer; 2020 Nov; 20(1):1102. PubMed ID: 33187507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis.
    St Romain P; Madan R; Tawfik OW; Damjanov I; Fan F
    Hum Pathol; 2012 Mar; 43(3):398-404. PubMed ID: 21840040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
    Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
    Sanpaolo P; Barbieri V; Genovesi D
    Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis.
    Niikura N; Hayashi N; Masuda N; Takashima S; Nakamura R; Watanabe K; Kanbayashi C; Ishida M; Hozumi Y; Tsuneizumi M; Kondo N; Naito Y; Honda Y; Matsui A; Fujisawa T; Oshitanai R; Yasojima H; Tokuda Y; Saji S; Iwata H
    Breast Cancer Res Treat; 2014 Aug; 147(1):103-12. PubMed ID: 25106661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term prognoses and outcomes of axillary lymph node recurrence in 2,578 sentinel lymph node-negative patients for whom axillary lymph node dissection was omitted: results from one Japanese hospital.
    Ogiya A; Kimura K; Nakashima E; Sakai T; Miyagi Y; Iijima K; Morizono H; Makita M; Horii R; Akiyama F; Iwase T
    Breast Cancer; 2016 Mar; 23(2):318-22. PubMed ID: 25376341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
    Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
    Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal surveillance for postoperative metastasis in breast cancer patients.
    Makita M; Sakai T; Ogiya A; Kitagawa D; Morizono H; Miyagi Y; Iijima K; Iwase T
    Breast Cancer; 2016 Mar; 23(2):286-94. PubMed ID: 25294313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
    Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Borm GF; Tjan-Heijnen VC
    Breast Cancer Res Treat; 2013 Oct; 141(3):507-14. PubMed ID: 24104881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.
    Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K
    J BUON; 2013; 18(3):608-13. PubMed ID: 24065471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.
    Cancello G; Maisonneuve P; Rotmensz N; Viale G; Mastropasqua MG; Pruneri G; Montagna E; Dellapasqua S; Iorfida M; Cardillo A; Veronesi P; Luini A; Intra M; Gentilini O; Scarano E; Goldhirsch A; Colleoni M
    Breast Cancer Res Treat; 2011 Jun; 127(3):713-20. PubMed ID: 21452022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both?
    Raica M; Cîmpean AM; Ceausu RA; Fulga V; Nica C; Rudico L; Saptefrati L
    Anticancer Res; 2014 Mar; 34(3):1435-40. PubMed ID: 24596391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting axillary sentinel node status in patients with primary breast cancer.
    Kolarik D; Pecha V; Skovajsova M; Zahumensky J; Trnkova M; Petruzelka L; Halaska M; Sottner O; Otcenasek M; Kolarova H
    Neoplasma; 2013; 60(3):334-42. PubMed ID: 23374005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic relevance of peritumoral vascular invasion in immunohistochemically defined subtypes of node-positive breast cancer.
    Munzone E; Bagnardi V; Rotmensz N; Sporchia A; Mazza M; Pruneri G; Intra M; Sciandivasci A; Gentilini O; Luini A; Viale G; Veronesi P; Colleoni M
    Breast Cancer Res Treat; 2014 Aug; 146(3):573-82. PubMed ID: 25007961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of early distant metastasis in women with breast cancer.
    Rosa Mendoza ES; Moreno E; Caguioa PB
    J Cancer Res Clin Oncol; 2013 Apr; 139(4):645-52. PubMed ID: 23283528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.